Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2026
Event: Entry into a Material Definitive Agreement regarding debt financing to fund the pending acquisition of Amicus Therapeutics, Inc.
Key Financial Metrics and Capital Structure
This filing details a significant capital raise rather than operational financial results. Key figures include:
- Senior Notes Issued: $850 million aggregate principal amount of 5.500% Senior Notes due 2026.
- Term Loan B Facility: New $2 billion senior secured term loan.
- Term Loan A Facility: New $800 million senior secured term loan.
- Revolving Credit Facility: Expected new $600 million senior secured revolving credit facility (with an additional $150 million borrowing capacity for fees).
- Use of Proceeds: Funding the acquisition of Amicus Therapeutics, related fees, and borrowings under the new term facilities.
- Liquidity Status: Gross proceeds from the Notes are held in escrow pending the consummation of the acquisition.
Note: The filing does not provide current revenue, profit, cash flow, or margin data.
Material Changes and Transaction Details
The primary material change is the execution of a complex debt financing package to support a major M&A transaction.
- Acquisition Funding: The company is combining the new Notes, Term Facilities, and cash on hand to pay consideration for Amicus Therapeutics, Inc.
- Redemption Condition: If the acquisition is not completed by December 19, 2026, or upon certain other events, BioMarin must redeem all Notes at 100% of the initial issue price plus accrued interest.
- Covenants: The Indenture imposes strict limitations on the company's ability to incur additional debt, pay dividends, repurchase equity, make investments, incur liens, sell assets, or merge, unless the Notes receive investment-grade ratings.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The company intends to close the acquisition and utilize the new credit facilities. However, the filing includes standard forward-looking statement disclaimers regarding the timing and consummation of these transactions.
Risks and Contingencies:
- Transaction Failure: If the acquisition does not close by the specified deadline, the Notes become immediately redeemable.
- Events of Default: Defined triggers include failure to pay interest (30-day grace period), failure to pay principal, bankruptcy, or failure to pay judgments exceeding $125 million.
- Operational Restrictions: The new debt covenants significantly restrict corporate flexibility regarding dividends, asset sales, and further indebtedness until investment-grade ratings are achieved.
Investor Verification Checklist
- Verify the final closing date of the Amicus Therapeutics acquisition against the December 19, 2026, mandatory redemption deadline.
- Confirm the status of the $2.8 billion in new term loan facilities and the $600 million revolving facility.
- Review the full text of the Indenture (Exhibit 4.1) for specific covenant thresholds and potential waivers.
- Monitor for any updates on the investment-grade rating status of the Notes, which would suspend certain covenants.
- Check subsequent filings for any amendments to the acquisition agreement or financing terms.